Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib with Neoadjuvant Chemotherapy in TNBC
NCT02694224Phase 2Unknown
- Sponsor
- Universidad de Navarra
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vismodegib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Universidad de Navarra. Primary endpoint: Number of patients with treatment-related adverse events at 21 months. Status: unknown.
02
Drugs
vismodegib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02694224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694224.